These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29724869)

  • 1. Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
    Balasubramanian P; Nampoothiri RV; Goni D; Malhotra P
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29724869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
    Lu Q; Chen Y; Li Z
    Leuk Res; 2012 Jun; 36(6):e119-21. PubMed ID: 22386731
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
    Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
    Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
    Au WY; Chim CS; Lie AK; Liang R; Kwong YL
    Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous infiltration in acute promyelocytic leukemia.
    Ueda K; Kume A; Furukawa Y; Higashi N
    J Am Acad Dermatol; 1997 Jan; 36(1):104-6. PubMed ID: 8996272
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
    Naina HV; Levitt D; Vusirikala M; Anderson LD; Scaglioni PP; Kirk A; Collins RH
    J Clin Oncol; 2011 Jun; 29(18):e534-6. PubMed ID: 21482998
    [No Abstract]   [Full Text] [Related]  

  • 10. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
    [No Abstract]   [Full Text] [Related]  

  • 11. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
    Breccia M; Molica M; Efficace F; Minotti C; Latagliata R; Foà R; Lo Coco F
    Br J Haematol; 2014 Nov; 167(3):428-30. PubMed ID: 24957334
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
    Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA
    Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
    Kobayashi Y; Hatta Y; Ishizuka H; Hirabayashi Y; Tanaka T; Takei K; Takeuchi J
    Int J Hematol; 2010 Jan; 91(1):152-3. PubMed ID: 20033799
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
    Lin J; Zhu H; Li S; Fan H; Lu X
    Ann Hematol; 2014 Feb; 93(2):335-6. PubMed ID: 23719691
    [No Abstract]   [Full Text] [Related]  

  • 18. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
    Wang HX; Duan LN; Ji SQ; Guo ZK
    Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
    Kennedy GA; Marlton P; Cobcroft R; Gill D
    Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.